0%

est. 2Y upside i

HealthcareSeries A

Rank

#2267

Sector

Biotechnology / Synthetic Biology

Est. Liquidity

~3Y

Data Quality

Data: Low

Equity upside is highly uncertain due to lack of revenue data and stale valuation mark.

Last updated: July 3, 2026

Bull (10%)+180%

Strong platform adoption with major partnership; exit via acquisition at 3x entry valuation ($870M). Net of 20% dilution.

Base (55%)+30%

Gradual licensing deals; company continues as independent; valuation grows to 1.5x ($435M). Net of 20% dilution.

Bear (35%)-100%

Failure to secure major partnerships; competition from incumbents; company sold for assets at distressed price below $60M, common stock recovers nothing.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Funding Intensity

21%

Total preferred funding of $59.6M at 1x non-participating represents 20.6% of current $290M valuation, giving preferred investors priority in a downside exit.

Dilution Risk

high

Likely need to raise capital within 24 months given no new round since 2022, potentially adding 15-25% dilution from new investors.

Secondary Liquidity

none

No secondary market activity indicated; equity is illiquid until an exit event.

Questions to Ask at the Interview

Strategic questions based on 64x's data — designed to show you've done your homework.

  • 1

    “How would you prioritize which cell line engineering projects to pursue given limited resources?”

  • 2

    “What are the key drivers for licensing revenue vs. partnership milestones?”

  • 3

    “Given the company's pre-revenue status and long timeline, how do you evaluate the risk/reward of equity compensation?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.